IRD Opus Genetics Inc.

$IRD Leerink Partners analyst Lili Nsongo raised the 12-month price target from $14 to $15, maintaining a Buy rating. That's a 7.1% increase. JonesTrading also reaffirmed its Buy rating and $17 target today. Both actions are dated today October 19. Stock looks promising for long term. BULLISH AF

$IRD Weird stock. Nothing but great news and it either has a little pop or it goes down. One day this will run past $20. Bullish AF

$IRD BlackRock disclosed a significant ownership position in Opus Genetics in a new Schedule 13G filed today. Shares beneficially owned: 5,044,847 Ownership: 6.1% of outstanding common stock Sole voting power: 4,961,536 shares Reporting date: September 30, 2026 Filing date: October 27, 2026

$IRD faith turns into reality ! This will change so many lives…. Hopefully opening the door to cure all blindness. To top it off we make lots of money too! Lol

$IRD 🏥 Opus Genetics, Inc. received FDA clearance of its IND application for OPGx-RDH12 gene therapy for RDH12-associated Leber congenital amaurosis, enabling clinical development of the treatment for inherited childhood blindness. Curated for market relevance

$IRD Meta Muse suggested buying call contracts on this one due to upcoming FDA approval. It says that the approval chance is > 80%, and on approval chance of the stock reaching $8 upon approval is 80%. I am new to this forum. If anyone has any insights, can you share?

$IRD macros turning my opus into my oh pos. This will catch fire ah or tomorrow…FDA approval Friday (83% likely according to AI).

$IRD $3.51 was support previously, let’s if we get a reversal. Weak market and low volume bringing this down atm

$IRD if they get a $200 million voucher on LCA5 approval it is worth at least $200 million, that is $2 a share. If they are really funded through 2027 that could spin off $8 million a yr. LCA5, if approved will bring in $500 million over 12 to 24 months and has a very high net profit Best phase 3 starting, at a bare minimum of $1 million per procedure $10 to $24 billion If Viatris markets properly IRD could have $10’s of millions in royaly payments Just got to ride this market out

$IRD positive results in their clinical data for OPGx-Best1 and OPGx-LCA 5 gene therapy program time to fly tomorrow.

$IRD phentolamine is a once a day drop and lasts all day, it doesn’t have the side effects previous drops have had. Another benefit it doesn’t not effect the eye muscle. Every AI model I query expects peak US sales to be $500 million to $800 million. IRD royalties in the US appear to start at 12 percent scaling up to 20 percent net of cost I think. Global royalties 10 percent. Obviously not Viatris biggest drug but a nice addition News Friday or Monday potentially based on PDUFA date Correction on the value of the Voucher, upon approval of LCA5 the voucher is is automatic - last one sold for $200M There are currently no competition for any of the gene therapies. Best1 now has potential market of 24,000 people in the US alone. At over a $2 mil cost that is a serious market over a 3 to 4 yr period

$IRD BEST potential sales $50 billion plus - 22.000 patients at $2.5 mil LCA-5 sales potential $300 to $500 million a year In addition, the voucher they get upon approval will be worth over $125 million, which could be sold Ryzumvi PDUFA date by Monday Upon approval $10 million dollar payment Sales estimates range from $200 to $500 million plus a year. It appears to be better than other drops, as it lasts twice as long and does not stretch the muscle. Do your own research AI will confirm this They have other drugs in the pipeline

$IRD Latest company news, Oct 21, 2026: the FDA cleared Opus Genetics' IND for OPGx-RDH12, a gene therapy for inherited childhood blindness caused by RDH12 mutations; the company plans to start a Phase 1/2 trial this quarter. More news in our $IRD stock hub on Merlintrader. Not investment advice.

$IRD FDA approved Ryzumvi for presbyopia Friday, a day ahead of its Oct 17 target date. In VEGA-3, 27.2% of patients gained at least 15 letters of near vision vs 11.5% on placebo, with no serious treatment-related side effects. The approval still isn't a launch though. Viatris holds the US rights and said in the release it is exploring a partner to commercialize Ryzumvi for presbyopia, and IRD traded about 3.4% lower Friday after the news.

Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment $IRD $VTRS $XBI https://stocktwits.com/news/equity/markets/opus-genetics-secures-fda-approval-for-reading-vision-eye-drops-viatris-holds-us-commercial-rights/cZxKBzoRBsx

$IRD well I guess if it affected 92% of adults over 40 it would have some value, 90% not so much. Lol. This should blast after martini lunch hour.

$IRD am i the only one that knows this FDA approval "will trigger milestone payment to Opus Genetics "

$IRD feels good to own a $40 dollar stock when you only paid treefiddy. This lil fella is gonna be greener than sea sick Martian tomorrow.

$IRD It feels that those $.95 warrants that were exercised recently are being sold. George is an idiot for issuing shares sub $1.

$IRD Latest company news, Oct 21, 2026: in a Form 8-K, Opus Genetics said Ashwath Jayagopal left his role as Chief Scientific and Development Officer effective October 19, 2026, moving to a six-month consulting arrangement. More details in our $IRD stock hub. Not investment advice.